Exciting progress in the field of cancer immunotherapy has renewed the urgency of the need for basic studies of immunoregulation in both adaptive cell lineages and innate cell lineages. Here we found a central role for major histocompatibility complex (MHC) class I in controlling the phagocytic function of macrophages. Our results demonstrated that expression of the common MHC class I component β 2 -microglobulin (β 2M) by cancer cells directly protected them from phagocytosis. We further showed that this protection was mediated by the inhibitory receptor LILRB1, whose expression was upregulated on the surface of macrophages, including tumor-associated macrophages. Disruption of either MHC class I or LILRB1 potentiated phagocytosis of tumor cells both in vitro and in vivo, which defines the MHC class I-LILRB1 signaling axis as an important regulator of the effector function of innate immune cells, a potential biomarker for therapeutic response to agents directed against the signalregulatory protein CD47 and a potential target of anti-cancer immunotherapy.
W hen properly stimulated, effector cells of both the innate immune system and adaptive immune system possess the ability to attack cancer cells. Clinical successes have highlighted the potential of this approach, but more complete understanding of immunoregulation is critical for the development of new therapeutic strategies.
Tumor-binding antibodies have been used in the clinic to treat many cancers, including lymphomas, breast cancer and colon cancer, among others 1 . These antibodies often exhibit multiple modes of action, but their efficacy is linked, in part, to their ability to stimulate antibody-dependent cellular phagocytosis of cancer cells 2 . However, the potency of this response is dampened by the expression, on the surface of cancer cells, of the signal-regulatory protein CD47, which engages the inhibitory receptor SIRPα on macrophages and functions as an anti-phagocytic 'don't eat me' signal 3, 4 . Therapeutic blockade of the CD47-SIRPα interaction greatly increases the antibody-induced phagocytosis of cancer cells both in vitro and in vivo [5] [6] [7] [8] . Biological agents directed against this axis are currently in clinical trials for multiple indications and represent a promising immunotherapeutic strategy 9 . However, redundant inhibitory signals are commonplace in immunoregulation, and the CD47-SIRPα axis is probably not the only important therapeutic target for engaging macrophages to attack cancer cells. In order to identify additional regulators of these cells, we undertook a targeted screen for cancer-relevant 'don't eat me' signals. Through this screen, we identified major histocompatibility complex (MHC) class I as a critical regulator of the effector function of macrophages within the tumor microenvironment.
Results
Expression of MHC class I correlates with resistance to phagocytosis. Drugs targeting the CD47-SIRPα pathway have broad efficacy in inducing the phagocytosis of cancer cells, yet some cells exhibit intrinsic resistance largely independent of disease subtype or tissue of origin [5] [6] [7] [8] . To investigate this phenomenon further, we assessed the phagocytosis, by primary human macrophages, of a diverse panel of human cancer cell lines. Phagocytosis was quantified by a flow cytometry-based assay validated by cell-sorting experiments 8, 10 and high-throughput microscopy ( Supplementary Fig. 1 ). We found that the clinical-stage CD47-blocking antibody Hu5F9-G4 (anti-CD47) 11 significantly increased phagocytosis of the majority of cancer cell lines tested (Fig. 1a) . However, despite the broad efficacy of this antibody, some cancer cell lines were not significantly phagocytosed after treatment with anti-CD47, and among the responding cell lines, the magnitude of induced phagocytosis varied widely (Fig. 1a) . These differences did not correlate with cancer subtype, nor did they correlate with surface expression of CD47, which was high in all cell lines tested ( Supplementary Fig. 2a ). Anti-CD47 induces phagocytosis both by blocking CD47-SIRPα signaling and by opsonizing cells via its functional immunoglobulin G4 crystallizable fragment (Fc) and thereby providing an 'eat me' signal that activates Fc receptors on macrophages. We therefore speculated that In order to identify those signals, we used an antibody array system to characterize the surface immunophenotype of five cell lines that spanned a broad spectrum of human tumor types and a wide range of sensitivity to phagocytosis after treatment with anti-CD47 (Hu5F9-G4): the colon-cancer lines DLD1 and HCT116; the smallcell lung-cancer lines NCI-H82 and NCI-H196; and the pancreatic neuroendocrine tumor line APL1 (ref. 12 ). In analyzing the data from these arrays, we identified a putative relationship between high expression of MHC class I proteins and resistance to anti-CD47-induced phagocytosis by macrophages ( Supplementary Fig. 2b ).
Engagement of MHC class I by the inhibitory receptor LILRB1 suppresses macrophages and is a target of cancer immunotherapy
HLA α -chains and β 2 -microglobulin (β 2M) assemble to form the MHC class I complex 13 , which has well-studied and essential roles in the regulation of T cells and natural killer (NK) cells but a comparatively limited function described for the regulation of macrophages 14, 15 . Nonetheless, analysis of HLA expression across our broader panel of 18 cancer cell lines revealed a highly significant correlation between overall levels of MHC class I and resistance to macrophage-mediated phagocytosis (Fig. 1b) . We observed no discernable relationship between the particular HLA phenotype of the cell lines and their sensitivity to phagocytosis (Supplementary Table 1 ). This correlation raised the possibility that expression of MHC class I is directly protective against macrophage attack.
MHC class I directly protects cells from macrophage attack.
In order to investigate the functional implications of the correlation noted above, we undertook a series of genetic experiments using two lines from our 'discovery panel': APL1 and DLD1. These lines were chosen because both are highly positive for expression of CD47, but APL1 cells naturally have high expression of MHC class I, while DLD1 cells are negative for surface expression of MHC class I due to biallelic inactivation of the B2M locus 16 . Through stable genome engineering and sequential rounds of sorting by flow cytometry, we generated polyclonal sub-lines of both APL1 cells and DLD1 cells with all four permutations of positive or negative expression of MHC class I and CD47 (Fig. 2a,b) .
Co-culture of those lines with donor-derived human macrophages revealed that in the absence of further stimulation, deletion of surface MHC class I was sufficient to modestly but significantly increase spontaneous phagocytosis in some cases (Fig. 2c) . We further found that MHC class I-negative (MHCI -) cells were significantly more sensitive to anti-CD47-induced phagocytosis than were their MHCI + counterparts (Fig. 2c,d ). After being treated with an independent opsonizing antibody, cells lacking expression of both CD47 and MHC class I were the most sensitive to phagocytosis, while expression of either MHC class I or CD47 or expression of both simultaneously provided significant protection against macrophage attack (Fig. 2e,f) . Thus, our data demonstrated that MHC class I and CD47 were independent anti-phagocytic signals that might also work cooperatively.
To extend those results, we generated a Fab fragment from a monoclonal antibody that blocks HLA-A, HLA-B and HLA-C 17, 18 . Consistent with our expectations, blockade via the HLA-binding Fab in absence of antibody Fc had no effect on the phagocytosis of the MHCI -cell line DLD1 (Fig. 2g) . However, when applied to a panel of MHCI hi cells ( Supplementary Fig. 2c ), the HLA-binding Fab significantly increased anti-CD47-induced phagocytosis for four of six lines tested (Fig. 2f) . Some cell lines (U2OS and SAOS2) were still resistant to phagocytosis after simultaneous blockade of CD47, blockade of MHC class I and opsonization (Fig. 2g) , which suggested that such cells probably expressed additional anti-phagocytic signals.
LILRB1 detects MHC class I and suppresses phagocytosis. In order to further investigate the phenomenon of the inhibition of macrophage phagocytosis by MHC class I, we sought to identify the receptor or receptors involved in the detection of MHC. Monocytelineage cells have been reported to express various MHC-binding proteins, notably members of the LILR family 19, 20 . Structural studies suggest that two members of this family, LILRB1 and LILRB2, bind MHC class I and also contain immunoreceptor tyrosine-based inhibitory motifs involved in the intracellular transduction of inhibitory signaling 20, 21 , which establishes them as strong candidates for MHC class I-mediated suppression of phagocytosis.
Analysis of human peripheral blood monocytes from four independent donors revealed that in addition to SIRPα , LILRB1 was expressed on the majority of monocytes, with only a subset being LILRB2 + (Fig. 3a,b) . Primary mature macrophages from normal human spleen were positive for SIRPα expression, and approximately one third of the cells were LILRB1 + ; nearly all cells were LILRB2 - (Fig. 3a,b) . In primary macrophages isolated from ascites fluid of patients with ovarian carcinoma, expression of both SIRPα and LILRB1 was uniformly positive and very high; in contrast, there was minimal expression of LILRB2 (Fig. 3a,b) . In tumorassociated macrophages from primary human colon carcinomas, we similarly saw higher expression of LILRB1 than of LILRB2 (Fig. 3a,b) . We observed no significant difference between M1-like tumor-associated macrophages and M2-like tumor-associated macrophages in their expression of LILRB1 or LILRB2 and detected 
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Nature ImmuNology no expression of either LILRB1 or LILRB2 by non-immune tumor cells ( Supplementary Fig. 3a,b) . The pattern of high expression of LILRB1 but low expression of LILRB2 was also replicated by ex vivodifferentiated primary macrophages ( Supplementary Fig. 3c,d ), which suggested that our in vitro experiments correctly reflected the expression profile of tumor-associated macrophages.
On the basis of those observations, we investigated whether direct blockade of LILRB1 could increase the phagocytosis of MHCI + cells. Indeed, we found that treatment with a blocking monoclonal antibody to LILRB1 (ref. 22 ) significantly increased the anti-CD47-induced phagocytosis of MHCI + cells but not that of their MHCI -counterparts ( Fig. 3c and Supplementary Fig. 3e ). As expected on the basis of the low or negative expression of LILRB2 by mature macrophages, treatment with an LILRB2-blocking antibody 23 had no significant effect on the phagocytosis of either MHCI + cells or MHCI -cells ( Fig. 3c and Supplementary Fig. 3e ).
In order to further investigate that relationship, we optimized and implemented a protocol to genetically modify the expression of LILRB1 in primary in vitro-derived human macrophages using the CRISPR-Cas9 ribonucleoprotein system. We observed a 42% reduction in population-wide expression of LILRB1 48 h following nucleofection with single guide RNA (sgRNA) targeting the LILRB1 locus, relative to its expression in cells treated with the control sgRNA (Supplementary Fig. 3f ). The corresponding knockout of LILRB1 in nearly 50% of alleles was confirmed through the use of TIDE software for quantitative assessment of genome editing 24 ( Supplementary Fig. 3g ). In the presence of anti-CD47-mediated blockade, LILRB1-null macrophages demonstrated significantly greater phagocytic ability than that of macrophages treated with the off-target control sgRNA (Fig. 3d) , which further demonstrated that the elimination of surface LILRB1 was sufficient to potentiate the phagocytosis of MHCI + cells in vitro. 
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Together these data identified LILRB1-and largely excluded the possibility of involvement of LILRB2-as a primary mediator of repressive MHC class I signaling in many human macrophage populations, especially in the context of cancer immunotherapy.
β2M confers species-specific protection against macrophages. The assays reported above used cells derived from multiple independent macrophage donors, with no prior analysis or matching between macrophages and cancer cells on the basis of HLA haplotype, which suggested a much broader mechanism for the detection of MHC class I by LILRB1 than that of the mostly allele-specific mechanisms employed by T cells and NK cells [25] [26] [27] . Consistent with that, examination of the previously solved crystal structure of LILRB1 bound to the human MHC class I complex 20 revealed that the majority of contact residues between LILRB1 and MHC class I were within the invariant β 2M subunit 28 rather than the highly polymorphic HLA α -chain (Fig. 4a) . Alignment of the human and mouse β 2M protein sequences revealed an identity mismatch of approximately 30%, including several key amino acids in the region of predicted contact between human β 2M and proteins of the LILRB family (Fig. 4a, inset) , which led us to hypothesize that these residues might be involved in species-specific signaling to macrophages.
Mouse β 2M is unable to form stable complexes with human HLA α -chains; transgenic expression of the gene encoding mouse β 2M in human β 2M -cells led to only low surface expression of MHC class I, as measured by an HLA-A-, HLA-B-and HLA-C-binding antibody ( Supplementary Fig. 4 ). To circumvent that limitation, we generated a chimeric β 2M in which the human β 2M protein was altered to include the amino acids of mouse sequence only within the predicted region of interaction with proteins of the LILRB family (Fig. 4a, inset) . Expression of the chimeric β 2M in either β 2M -parental DLD1 cells or in APL1 cells with deletion of B2M enabled robust surface expression of HLA comparable to that achieved with fully human β 2M protein (Fig. 4b) . However, unlike cells expressing fully human MHC class I, these chimeric MHC class I cells no longer interacted with an LILRB1-Fc fusion protein (Fig. 4b) , which suggested that they would probably no longer be efficiently protected from phagocytosis and raised the possibility that chimeric MHC class I complexes might, conversely, be recognized by mouse macrophages.
We confirmed that although expression of fully human β 2M strongly protected target cells against phagocytosis by human macrophages (Fig. 4c) , it was less efficient in protecting the target cells against mouse macrophages (Fig. 4c) ; in contrast, expression of chimeric Tumorassociated macrophages Articles Nature ImmuNology β 2M offered a more-efficient protection against mouse macrophages than against human macrophages (Fig. 4c) . Thus, the amino acid substitutions of the chimeric β 2M had switched the speciesspecific bias of this signaling interaction. This genetic analysis suggested that the amino acid residues in the LILRB-interacting region of β 2M were critical for the detection of MHC class I by both human macrophages and mouse macrophages.
MHC class I protects cells from macrophage attack in vivo.
Mice of the non-obese diabetic-severe combined immunodeficiency strain with homozygous deficiency in the gene encoding the common γ -chain (Il2rg Fig. 5d only) subcutaneously into NSG mice and used quantitative in vivo bioluminescent imaging to follow tumor growth. After several weeks, chimeric MHCI + tumors had grown significantly larger than MHCI -tumors had (Fig. 5a ); this growth difference ultimately manifested as a significant survival advantage for mice engrafted with MHCI -tumors (Fig. 5b) . We also injected a mixed population of cells composed of 50% MHCI -cells and 50% human-mouse chimeric MHCI + cells into host mice and followed the evolution of these tumors over time. Tumors initially contained an approximately equal frequency of MHCI + cells and MHCI -cells (Fig. 5c,d , pre-injection and day 7), but after several weeks of growth, the tumors had become almost uniformly MHCI + , as measured by flow cytometry (Fig. 5c,d, Fig. 5a ). Furthermore, expression of fully human MHC class I, rather than human-mouse chimeric MHC class I, provided no significant growth advantage relative to the growth of MHCI -cells in vivo ( Supplementary Fig. 5b ). Along with the fact that NSG mice lack all immune cell subsets classically considered the main sensors of MHC class I (for example, T cells or NK cells) and that we readily observed phagocytosis of tumor cells by macrophages, via histology ( Supplementary Fig. 5c ), these results supported the proposal of a macrophage-mediated, MHC class I-driven immunosurveillance mechanism.
In order to determine whether the protection against phagocytosis and tumor growth conferred by the chimeric MHC class I complex could also be recapitulated in a syngeneic mouse system, we generated stable lines of the mouse melanoma B16-F10 with all four permutations of positive or negative expression of mouse MHC class I and CD47 (Fig. 6a) and engrafted them into lymphocytedeficient (Rag2
Il2rg
-/-) mice. After 20 d of in vivo growth, there was no significant difference between the volume of β 2M -tumors and that of CD47 -tumors (Fig. 6b) . However, tumors lacking both β 2M and CD47 grew significantly less than wild-type tumors did (Fig. 6b) . Given that Rag2
-/-hosts lack NK cells, innate lymphoid cells and T cells, this effect served as demonstration of a macrophage-mediated, MHC class I-regulated anti-tumor effect.
We next sought to investigate the therapeutic potential of antagonizing the signaling axis noted above in an immunocompetent in vivo model. In contrast to studies of lymphocyte-free models, studies of immunocompetent hosts can elucidate the contributions of additional cell types such as T cells and NK cells and can serve as a system with which to investigate communication and supportive signaling between the adaptive immune system and innate immune system. 
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In order to parse the individual anti-tumor effects of macrophages and NK cells, we compared the engraftment and growth of wild type, B2m
Cd47
-/-and B2m
-/-B16-F10 tumors in fully immunocompetent hosts and wild-type hosts depleted of NK cells or macrophages.
At 25 d after engraftment, we observed that the growth of wildtype B16-F10 tumors was significantly greater after depletion of either NK cells or macrophages (Fig. 6c) , which demonstrated that both cell types contributed to anti-tumor immunity in this model. We hypothesized that although deletion of B2m might sensitize tumor cells to killing by either NK cells or macrophages, it also liberated them from detection and killing mediated by the T cell antigen receptor. Indeed, we found that tumors in which B2m was deleted grew larger than did wild-type tumors and were not significantly affected by depletion of either macrophages or NK cells (Fig. 6c) . In contrast, for tumors in which both B2m and Cd47 were deleted, depletion of macrophages significantly reduced anti-tumor immunity and led to increased tumor growth, but depletion of NK cells did not (Fig. 6c) .
We also compared the engraftment and growth of B2m
-/-B16-F10 tumors in fully immunocompetent hosts with that in Ccr2 -/-hosts, which are specifically defective in the tumor-homing activity of monocyte-derived macrophages.
We observed no significant difference in the engraftment or growth of wild type B16-F10 cells in immunocompetent hosts relative to their engraftment and growth in Ccr2 -/-hosts, but B2m
and B2m
-/-tumors showed significantly greater engraftment and growth in the Ccr2 -/-hosts than in immunocompetent hosts ( Supplementary Fig. 6a ). Together these findings confirmed an important macrophage-mediated role for MHC class I signaling and, together with our in vitro data, supported the proposal of cooperativity of the MHC class I and CD47 signaling axes.
In addition to assessing net effects on tumor mass, we were able to investigate the effect of deletion of B2m and Cd47 on the infiltration of a variety of subpopulations of immune cells in surviving mice. Analysis of dissociated tumors from immunocompetent hosts by flow cytometry demonstrated that specifically in B2m
-/-tumors, there was increased infiltration of all varieties of immune cells assessable by our marker panel. In particular, this increase included immune cells involved in the adaptive immune response, such as T cells and dendritic cells ( Fig. 6d ; gating strategy, Supplementary Fig. 6e ). Critically, these effects were abolished by depletion of macrophages (Fig. 6d) , suggestive of an important immunoregulatory role for these cells in the tumor microenvironment Articles Nature ImmuNology that was influenced by signaling via MHC class I and CD47 to macrophages. Elimination of multiple 'don't eat me' signals might thus lead macrophages to promote a robust shift toward a more immunogenic, anti-tumor phenotype.
The polarization of macrophages to either an inflammatory, M1, 'anti-tumor' state or anti-inflammatory, M2, 'pro-tumor' state has an important role in the net effect of macrophages on the tumor microenvironment 30 , and we hypothesized that inhibitory signaling through LILRB1 might contribute to a tumor-promoting macrophage phenotype. Analysis by flow cytometry revealed that deletion of LILRB1 from macrophages in vitro resulted in a significantly greater abundance of cells with an M1-like surface profile than that among macrophages treated with an off-target control sgRNA ( Supplementary Fig. 6b ). Given that we observed this shift in the absence of non-macrophage cells, this result was consistent with a possible role either for in cis LILRB1-MHC class I signaling or perhaps signaling between LILRB1 and MHC class I on adjacent macrophage cells in culture.
Discussion
The data presented here have demonstrated MHC class I to be a regulatory signal for the effector functions of macrophages and have thus expanded the understanding of one of immunology's best-studied and most important signaling complexes, and have also highlighted the central role of MHC class I in coordinating the activity of both the adaptive immune system and the innate immune system. MHC class I-LILRB1 signaling has been previously studied in a subset of NK cells 17, 31, 32 , and it has been studied in the myeloid lineage for its role in monocyte activation 19 . Our data suggest that the regulation of phagocytosis by macrophages is an additional key role of LILRB1 signaling. LILRB1 recognizes a wide variety of HLA haplotypes 33 due to its interaction with the invariant β 2M subunit of MHC class I 20 , which suggests that this signaling axis is relevant across diverse patient populations.
Although we were able to demonstrate that the MHC class I-tomacrophage signaling axis was active in both immunocompromised mice and immunocompetent mice, in our current work we did not identify the functional equivalent of human LILRB1 in mouse macrophages. Several candidates, including the mouse receptor PirB, have been reported to bind MHC class I 34 and have expression patterns in immune cells consistent with a LILRB1-like function. However, full characterization of the mouse system will be an important step in understanding signaling via MHC class I to macrophages during normal immunity and in the tumor microenvironment. 
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Our results have important implications for several aspects of macrophage biology. Viruses can avoid the presentation of foreign peptides to T cells by the downregulation of surface MHC class I, which can consequently activate NK cell attack due to lack of binding of MHC by killer-cell immunoglobulin-like receptors 35 . We hypothesize that the MHC class I-LILRB1 signaling axis might serve a similar role in the immunosurveillance of infected cells. Consistent with our hypothesis, the human cytomegalovirus (CMV) family has evolved to encode a protein, UL-18, that structurally mimics the MHC class I α -chain but prevents binding by T cells 20 . It binds LILRB1 with > 1,000-fold higher affinity than do native MHC complexes and, according to published reports, inhibits the subset of NK cells that express LILRB1 (ref.
32
). Given the high expression of LILRB1 in mature macrophages, UL-18 probably similarly modulates the macrophage-mediated phagocytosis of CMV-infected cells, which might influence the pathology of CMV infection.
MHC class I-LILRB1 signaling is also probably important in the dynamics of programmed cell removal. As erythrocytes age, their effective CD47 signaling gradually decreases and eventually drops below a critical threshold, which enables the phagocytosis of red blood cells by macrophages 4, 36 . The majority of normal human cells, including erythrocyte precursors, express MHC class I, but mature red blood cells lack or have considerably diminished surface expression of this protein. This loss of MHC class I during erythrocyte differentiation might serve to explain the potent erythrophagocytosis and transient anemia induced by anti-CD47 or CD47-binding Fc fusion proteins when used as cancer therapy 7, 8 . As demonstrated by our results both in vitro and in vivo, loss of MHC expression sensitized cancer cells to macrophage attack. Many cancers exhibit compromised or absent expression of surface MHC 37,38 and, due to the resulting impaired presentation of cancer neo-antigens, patients with such cancers might be poor candidates for T cell-focused therapies. However, our results suggest that they might in fact be the ideal candidates for macrophage-mediated immunotherapy, and thus while low MHC expression might be used as a negative biomarker for the efficacy of T cell-focused therapies, it might instead be a positive biomarker for the efficacy of anti-CD47 or anti-SIRPα drugs in development. SIRPα and LILRB1 also show variable expression in primary patient macrophages, probably due to variable conditions of immunological and inflammatory signaling, and might themselves be useful biomarkers.
In patients with tumors that have normal or high expression of MHC class I, agents directed against the MHC class I-LILRB1 axis might facilitate an anti-tumor immune response and could potentially act together with agents directed against CD47 or SIRPα . Like CD47, MHC class I is ubiquitously expressed by normal cells; in considerations of this axis as a therapeutic target, key questions arise about safety and specificity. To this point, we note that apart from depletion of MHCI -erythrocytes, which would not be further exacerbated by blockade of MHC class I-LILRB1 signaling, toxicity in normal tissues has thus far not been reported for anti-CD47 agents in animal models 7, 8 . This is despite the fact that some normal cells, such as those of the central nervous system, have low expression of MHC class I. We also note that B2m -/-mice have been reported to present few if any phenotypes that are attributable to the attack of normal cells by macrophages 39, 40 . Finally, our in vitro experiments demonstrated that some cell lines (U2OS and SAOS2) remained highly resistant to phagocytosis even after simultaneous blockade of both CD47-SIRPα and MHC class I-LILRB1 signaling, a result potentially consistent with the expression of additional, as-yetunidentified 'don't eat me' signals. Normal tissues might similarly express such redundant signals. Nonetheless, careful evaluation of macrophage-mediated autoimmune responses will be a critical subject of future work on this signaling axis.
The immunotherapy field has been energized by the tremendous success of T cell-mediated anti-cancer treatments, and the innate immune system presents a substantial future therapeutic opportunity. Macrophage antibody-dependent cellular phagocytosis can increase the cross-presentation of tumor antigens to T cells and might thereby enhance the potency of an adaptive antitumor immune response 41 . Our results indicate that blocking both the MHC class I-LILRB1 signaling axis and CD47-SIRPα signaling axis might sensitize tumors to macrophage attack and might indirectly enhance the function of other immune cells. If properly applied, agents directed against the MHC class I-LILRB1 signaling axis might be an important component of therapeutic regimens that aim to engage the key effector functions of macrophages.
Methods
Methods, including statements of data availability and any associated accession codes and references, are available at https://doi. org/10.1038/s41590-017-0004-z.
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Methods
Cell culture. All cell lines were obtained from ATCC with the exception of APL1, which was a gift from G. Krampitz (Stanford University) 12 . DLD-1, NCI-H69, NCI-H82, NCI-H1688, NCI-H196, NCI-H524, Bon and APL1 cells were grown in RPMI + GlutaMax (Life Technologies) supplemented with 10% FBS (Hyclone) and 100 U/ml penicillin and streptomycin (Life Technologies). NCI-H128 cells were grown in RPMI + GlutaMax (Life Technologies) supplemented with 20% FBS (Hyclone) and 100 U/ml penicillin and streptomycin (Life Technologies). HT-29, SkBr3 and SkMel3 cells were grown in McCoy's 5A + GlutaMax (Life Technologies) supplemented with 10% FBS (Hyclone), and 100 U/ml penicillin and streptomycin (Life Technologies). LS-174T, MCF7 and SkMel28 cells were grown in Eagle's Minimum Essential Media (ATCC) supplemented with GlutaMax (Life Technologies), 10% FBS (Hyclone) and 100 U/ml penicillin and streptomycin (Life Technologies). When necessary, cells were detached from plates and disaggregated using TrypLE Express (Life Technologies) according to the manufacturer's indications. Unless otherwise indicated, cell lines were propagated and subcultured according to ATCC guidelines.
Generation of lentiviral particles. HIV-based replication-incompetent lentiviral particles were generated in 293 Lenti-X cells (Clontech) by co-transfection of pMDG.2 vector (Addgene), psPAX2 (Addgene) and a third vector specific to the lentiviral application, using the Xtremegene HD transfection reagent (Roche) according to the manufacturer's protocol. Vectors were transfected at a mass ratio of 4:2:1, lenti-specific vector:psPAX2:pMDG.2. After transfection, cell culture media supernatant was collected at 36 h and 60 h. Lentiviral particles were concentrated either by ultracentrifugation for 2.5 h at 50,000g or with PEGit (Systems Biosciences) according to the manufacturer's indications. Proper biosafety and disposal techniques were followed whenever using lentiviral reagents, according to Stanford University guidelines.
Generation of DLD1 and APL1 cell sub-lines. In order to generate sub-lines of DLD1 and APL1 cells, parental, unmodified cells were harvested in singlecell suspensions and were mixed with pre-warmed growth media, concentrated lentivirus and 10 μ g/ml polybrene (Sigma). Cells were then centrifuged at 1,800 r.p.m., room temperature for 45 min. Lentiviral pools included at least three distinct viral species: one encoding the Cas9 nuclease, and two others encoding different CRISPR small guide RNAs (sgRNAs) targeting the first exon of either CD47 or B2M, as appropriate. CRISPR sgRNAs were designed using online tools (http://genome-engineering.org) and were of the following sequences: sgCD47-1: GCTACTGAAGTATACGTAAAG, sgCD47-2: GCTTGTTTAGAGCTCCATCAA, sgβ 2M-1: GAGTAGCGCGAGCACAGCTA, sgβ 2M-2: GGCCGAGATGTCTCGCTCCG. 7 d after infection, cells were assessed for expression status by flow cytometry. CD47 was assessed by staining with APCconjugated B6H12 (Biolegend), and HLA-A, HLA-B and HLA-C was assessed by staining with PE-Cy7-conjugated W6/32 (Biolegend). Cells were sorted on a FACSAria II cell sorter (BD Biosciences). Typically, each cell line was sorted three times, separated by several days of recovery and expansion between rounds. Wild-type human B2M (NC_000015.10), wild-type mouse B2m (NC_000068.7), or chimeric human-mouse B2M (hmcβ 2M; sequence below) were cloned into the NheI and NotI sites of the pCDH-CMV-MCS-EF1-Puro vector (Systems Biosciences), and these vectors were used to produce lentivirus and introduce transgenes, as appropriate. DLD1-Δ (CD47) was generated by transient cotransfection of CD47-targeting TALEN vectors, described below, using Xtremegene HD (Roche) according to the manufacturer's indicated protocol. All other genetic modifications were induced using lentiviral delivery of transgenes, or lentiviral delivery of Cas9 and corresponding sgRNAs, as described above.
TALEN design and construction. TALENs were designed and assembled as described 29 . The genomic locus of human CD47 (NC_000003.12) was scanned for putative TALEN binding pairs. Exon 2 was ultimately selected for targeting and the TALEN pairs TGTCGTCATTCCATGCTTTG and TATACTTCAGTAGTGTTTTG were respectively cloned into the pTALEN backbone.
GFP-luciferase and RFP-luciferase transduction. In order to facilitate both the flow cytometry-based phagocytosis assay and in vivo imaging, we generated sublines of DLD1, HT-29, LS-174T, SkBr3, Bon, APL1, SkMel28 and SkMel3 cells engineered via lentiviral infection to stably express a green fluorescent protein (GFP)-luciferase fusion protein (Systems Biosciences, catalog number BLIV100PA/VA-1). U2OS and SAOS2 were engineered via lentiviral infection to stably express a red fluorescent protein (RFP)-luciferase fusion protein (Systems Biosciences, catalog number BLIV101PA/VA-1). The MHCI-APL1 cells used in Fig. 5d were engineered to express both GFP-luciferase and RFP-luciferase with the vectors described above. Parental cells were harvested in single-cell suspensions and were mixed with pre-warmed growth medium, concentrated lentivirus and 10 μ g/ml polybrene (Sigma). Cells were then centrifuged at 1,800 r.p.m., room temperature for 45 min. Uniform GFP + or RFP + populations were then generated by sequential rounds of cell sorting on a FACSAria II cell sorter (BD Biosciences).
Macrophage generation. Leukocyte reduction system (LRS) chambers from anonymous donors were obtained from the Stanford Blood Center. Monocytes were purified from these samples on an autoMACS Pro Separator (Miltenyi) using anti-CD14 microbeads optimized for whole-blood separation (Miltenyi) according to the manufacturer's suggested protocol. Monocytes were then differentiated to macrophages by 7-10 d of culture in IMDM + GlutaMax (Life Technologies) supplemented with 10% AB Human Serum (Life Technologies) and 100 U/ ml penicillin and streptomycin (Life Technologies). NSG macrophages were generated as previously described 17 . In brief, bone marrow cells were harvested from the lower limbs of 6-to 8-week-old NSG mice, and were cultured for 7 d in IMDM + GlutaMax 13 (Life Technologies) supplemented with 10% FBS (Hyclone), 100 U/ml penicillin and streptomycin and 10 ng/ml murine M-CSF (Peprotech).
Flow cytometry-based phagocytosis assay. Each phagocytosis reaction reported in this work was performed by co-culture of 100,000 target cells and 50,000 macrophages for 2 h in ultra-low-attachment 96-well U-bottom plates (Corning) in IMDM + GlutaMax (Life Technologies) without antibiotics or serum added. Macrophages were generated as described above and were harvested from plates using TrypLE Express (Life Technologies). Target cells were either engineered to stably express GFP or RFP, as described above, or were stained with Calcein AM (Life Technologies) according to the manufacturer's indications before co-culture. Treatment antibodies, including anti-CD47 (clone Hu5F9-G4, cetuximab, BristollMyers Squibb), anti-LILRB1 (clone GHI/75, BioLegend) and anti-LILRB2 (clone 27D2, Biolegend) were added to reactions at a concentration of 10 μ g/ml. After co-culture, reactions were stained were stained with APC-labeled anti-CD45 (clone HI30, BioLegend) to identify human macrophages, and with PE-Cy7-labeled anti-F4/80 (clone BM8, BioLegend) to identify NSG mouse macrophages. DAPI staining was used to exclude dead cells from the analysis (Sigma). Reactions were run on an LSRFortessa Analyzer outfitted with a high-throughput auto-sampler (BD Biosciences). Phagocytosis was evaluated as a sum of the GFP + macrophages, expressed as a percentage of the total macrophages, as analyzed using FlowJo v.9.4.10 (Tree Star) and was normalized as indicated in the figure legends. Unless otherwise stated, each replicate represents a true biological replicate (i.e., an independent human macrophage donor), and unless otherwise indicated, replicates were split between a minimum of two independent experimental instances (for example, four independent donors evaluated on day 1, with an additional four independent donors evaluated on day 2). Sample size was chosen to ensure a greater than 95% probability of identifying, by the two-tailed t-test, an effect of > 20%, assuming a technical variation of 15%.
Antibody array. We used the LegendScreen antibody array system (BioLegend) to assess the surface phenotype of the NCI-H69, NCI-H82, NCI-H524 and NCI-H196 cell lines. The cells were harvested and disaggregated with TrypLE (Life Technologies), and NCI-H82 and NCI-H69 cells were stained using Calcein AM (Life Technologies) according to the manufacturer's protocol. NCI-H82 (calceinstained) cells and NCI-H524 (unstained) cells were run together in a multiplex fashion, as were NCI-H69 (calcein-stained) cells and NCI-H196 (unstained) cells. Cells were distributed among antibody-containing wells, then were stained and washed according to the manufacturer's indications. Samples were subsequently run on an LSRFortessa Analyzer outfitted with a high-throughput auto-sampler (BD Biosciences). Fluorescence levels were evaluated using FlowJo v.9.4.10 (Tree Star). Calcein staining signal was used to deconvolute multiplexed samples. Human-mouse chimeric β2M. Chimeric β 2M was designed to incorporate C-terminal amino acid differences from mouse β 2M into a primarily human β 2M sequence. The sequence (indicated below) was chemically synthesized (IDT), and cloned into the NheI and NotI sites of pCDH-CMV-MCS-EF1-Puro. Sequence of mouse origin is in lower case.
> hmcβ 2M_geneblockTTTAAGCTAGCATGTCTCGCTCCGTGGCCTTAGC TGTGCTCGCGCTACTCTCTCTTTCTGGCCTGGAGGCTATCCAGCGTACT CCAAAGATTCAGGTTTACTCACGTCATCCAGCAGAGAATGGAAAGTCA For flow cytometry-based phagocytosis assays, sample size was chosen to ensure a greater than 95% probability of identifying, by two-tailed t-test, an effect of >20% between treatment conditions, assuming a technical variation of 15%. Unless otherwise indicated, phagocytosis experiments were performed using eight biological replicates (i.e. independent macrophage donors). For in vivo experiments, sample size was chosen to ensure a greater than 95% probability of identifying, by two-tailed t-test, an effect between cell lines of >50%, assuming a technical variation of 50%.
Data exclusions
Describe any data exclusions. In some cases, additional replicates of specific experimental conditions (e.g. DLD1 phagocytosis assay with human macrophages, PBS treated versus Hu5F9-G4-treated) were repeated many times as control, or as part of pilot experiments, or as confirmatory replicates, but only a discrete set of data (e.g. DLD1 phagocytosis assays with eight independent macrophage donors, performed under identical conditions across two distinct experimental instances) was specifically reported. For in vivo experiments, in some cases across additional experiments, including pilot experiments, additional mice were engrafted subcutaneously with relevant cell lines and followed for non-standard periods of time, or assessed for tumor growth at non-standard intervals, or injected with antibody adjuvant treatments, but only a discrete set of mice assessed under identical conditions was reported. Upon reviewer request, both subcutaneous and intravenous injection of B16-F10 cells followed by treatment with antibody TA99 were performed, but were ultimately not reported in the final manuscript.
Replication
Describe whether the experimental findings were reliably reproduced.
Unless otherwise indicated, all in vitro experiments were performed in multiple biological replicates, across multiple experimental instances. In the case of in vivo experiments, wherever practical multiple cohorts across multiple experimental instances were performed.
Randomization
Describe how samples/organisms/participants were allocated into experimental groups.
Following engraftment and initial tumor measurement (when relevant), mice were randomized into treatment cohorts using the list randomization tools at random.org.
Blinding
Describe whether the investigators were blinded to group allocation during data collection and/or analysis.
All experiments, including in vivo experiments in mice, were performed in a nonblinded fashion.
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Statistical parameters
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the Methods section if additional space is needed).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided (note: only common tests should be described solely by name; more complex techniques should be described in the Methods section)
A description of any assumptions or corrections, such as an adjustment for multiple comparisons
The test results (e.g. P values) given as exact values whenever possible and with confidence intervals noted A clear description of statistics including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
Clearly defined error bars
See the web collection on statistics for biologists for further resources and guidance.
Software
Policy information about availability of computer code
Describe the software used to analyze the data in this study.
Flow cytometry data was analyzed using FACSDiva (BD) and FlowJo (Tree Star). Graphs and statistical analysis were generated using Prism (GraphPad). CRISPR deletion analysis was performed using the published TIDE software, as described in the references and methods.
For manuscripts utilizing custom algorithms or software that are central to the paper but not yet described in the published literature, software must be made available to editors and reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). Nature Methods guidance for providing algorithms and software for publication provides further information on this topic.
Materials and reagents
Policy information about availability of materials
Materials availability
Indicate whether there are restrictions on availability of unique materials or if these materials are only available for distribution by a for-profit company.
APL1 cells are not available from public sources, but are available from Irving Weissman upon request.
Antibodies
Describe the antibodies used and how they were validated for use in the system under study (i.e. assay and species).
Hu5F9-G4 is a clinical stage humanized anti-human CD47 antibody, and was validated as described in Liu et al. PLoS One (2015) . Surface CD47 levels were assessed by antibody staining with clone B6H12 (BioLegend) at a dilution of 1:100; this antibody was validated by comparing flow cytometry staining of unmodified versus CD47 knock out cells. HLA-A/B/C was assessed by antibody staining with clone W6/32 (BioLegend) at a dilution of 1:50; this antibody was validated by comparing flow cytometry staining of unmodified versus B2M knockout cells. LILRB1 was assessed by antibody staining with clone GHI/75 (BioLegend) at a dilution of 1:25; this antibody was validated by comparing flow cytometry staining of non-myeloid versus myeloid cells, and normal macrophages versus macrophages electroporated with LILRB1-targeting CRISPR complexes. LILRB2 was assessed by antibody staining with clone 27D2 (BioLegend) at a dilution of 1:25; this antibody was validated by comparing flow cytometry staining of non-myeloid versus myeloid cells. All other antibody clones (e.g. immune subset markers, IgG controls) were used based on literature reports or data from manufacturer, and were not independently validated for the purposes of this study.
a. State the source of each eukaryotic cell line used. All cell lines were obtained from ATCC, with the exception of APL1, which was derived from a primary patient tumor as described in Krampitz et al. PNAS (2016) .
b. Describe the method of cell line authentication used. Cell lines were not independently authenticated, beyond the identity provided from the supplier (e.g. ATCC).
c. Report whether the cell lines were tested for mycoplasma contamination.
Stocks of all cell lines were tested for mycoplasma contamination prior to submission. All were negative.
d. If any of the cell lines used are listed in the database of commonly misidentified cell lines maintained by ICLAC, provide a scientific rationale for their use.
No cell lines used in this study are in the database of commonly misidentified cell lines.
Animals and human research participants
Policy information about studies involving animals; when reporting animal research, follow the ARRIVE guidelines
Description of research animals
Provide details on animals and/or animal-derived materials used in the study.
Relevant information regarding animals and animal experiments are described throughout manuscript and methods.
Policy information about studies involving human research participants
Description of human research participants
Describe the covariate-relevant population characteristics of the human research participants.
No human research subjects were utilized in this work.
